Vigil Neuro
Jennifer has more than 25 years of experience in various cross-functional finance and operational leadership roles. Prior to joining Vigil, Jennifer was Chief Financial Officer of Solid Biosciences, where she played a key role in transforming Solid from a private, preclinical company to a publicly-held, clinical-stage biotech company. She was responsible for finance, accounting, investor relations, corporate communications, and business development and executed a wide range of financial and strategic transactions during her tenure. Previously, she served as the Head of Sales Operations, North America for Philips Healthcare after holding various leadership roles across several of the company’s businesses. Prior to Phillips, Jennifer was Senior Director of Finance and Corporate Controller at TransMedics, Inc., where she played a critical role in building the company’s financial operations. She established her career within the healthcare industry at Cytyc Corporation. Jennifer began her career at PricewaterhouseCoopers LLP and has a Bachelor of Science degree in Accounting from Boston College. She is a Certified Public Accountant (CPA).
This person is not in any offices
Vigil Neuro
Vigil Neuroscience is the world’s first microglia-focused therapeutics company. Their purpose is clear: to treat rare and common neurodegenerative diseases by restoring the vigilance of the microglia, the sentinel cells of the brain’s immune system. They are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and their families.